The Mutaflor^® – Escherichia coli (Nissle 1917), serotype O6:K5:H1 – the best researched probiotic available

Czech version

Authors: M. Lukáš
Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s., Praha
Published in: Gastroent Hepatol 2016; 70(3): 281-282
Category: Drug Profile
doi: https://doi.org/10.14735/amgh2016281

Sources

1. Nissle A. Über die Grundlagen einer neuen ursachlichen Bekampfung der pathologischen Darmflora. Dtsch Med Wochenschr 1916; 42: 1181– 1184.

2. Kruis W, Frič P, Pokrotniekes J et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53(11): 1617– 1623.

3. Matthes H, Krummenerl T, Giensch M et al. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement and Altern Med 2010; 10: 13. doi: 10.1186/ 1472-6882-10-13.

4. Cukrowska B, Lodlnová-Zadnikova R, Enders C et al. Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917. Scand J Immunol 2002; 55(2): 204– 209.